Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585910 · ClinicalTrials.gov registry record · Phase 4
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 94
- Enrollment target
NCT00585910: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00585910 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 94 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00585910, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
Interventions
- DRUG Atomoxetine and OROS Methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585910
The ClinicalTrials.gov registry entry for NCT00585910 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atomoxetine and OROS Methylphenidate is the first listed.
NCT00585910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585910 about?
NCT00585910 is a clinical study titled "Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD". The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
What is the current status of trial NCT00585910?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 94 participants. The study started on 2004-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00585910?
The interventions under investigation include: Atomoxetine and OROS Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00585910?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.